Download presentation
Presentation is loading. Please wait.
Published byYadira Cashmore Modified over 9 years ago
1
Treating Life Threatening Asthma Toni Petrillo-Albarano, MD Division of Pediatric Critical Care Children’s Healthcare of Atlanta
2
Asthma: Increased Severity Hospitalization Increased 28% -MMWR, CDC
3
Asthma: Increased Severity Death Rate Increased 118% (1980 - 1993) -MMWR, CDC
4
The Cost of Asthma Asthma related costs $6.2 billion Direct 3.6 billion Indirect $2.6 billion Pediatric $465 million
5
Children Who Die from Asthma Risk Factors: Severe disease - history of intubation, seizures, rapid progress Lack of adequate support systems Psychologic disease
6
Children Who Die from Asthma Risk Factors: Lack of perception of severity; self- weaning Males Exclusive reliance on b agonists 50% of deaths prior to hospital
7
Mechanisms of Status AsthmaticusMucousHypersecretion Bronchospasm Mucosal edema Increased resistance to air flow Atelectasis Uneven ventilation Abnormal V/Q Hyperinflation deadspacecompliance alveolar hypoventilation WOB pCO 2 pO 2
8
Status Asthmaticus Oxygen Relative hypoxemia: V/Q mismatch hypoventilation Hypoxemia bronchoconstriction agonists impair hypoxic pulmonary vasoconstriction shunt Oxygen to keep pulse ox > 92%
9
Status Asthmaticus Beta 2 Agonist Therapy Mainstay of therapy Rapid onset Selective 2 : metaproterenol terbutaline albuterol Mode of delivery: inhaled vs systemic intermittent vs continuous nonintubated vs intubated
10
Intravenous Agonists Most studies: inhaled therapy > to IV agonist Greater side effects with IV Potential benefit severe bronchospasm Experience anecdotal with severe SA IV Terbutaline: bolus 10 mcq/kg infusion 0.1-4.0 mcq/kg/min
11
Status Asthmaticus Isoproterenol (Isuprel) Almost pure effects Potent vasodilator pulmonary bronchial Increased cardiac output Widened pulse pressure Increases flow to noncritical tissue beds (skeletal muscle)
12
Status Asthmaticus Isoproterenol (Isuprel) Tachycardia Dysrhythmias Peripheral vasodilation Increased myocardial O 2 consumption Decreased coronary O 2 delivery “Splanchnic steal” by skeletal muscle
13
Severe Asthma Intravenous Isoproterenol Equivocal results high incidence of dysrhythmias report of fatal myocardial ischemia “DO not use IV Isuprel in the treatment of asthma...” -NHLBI statement
14
Status Asthmaticus Subcutaneous Agonists Epinephrine/terbutaline No advantage over inhaled agonists Increased side effects Indications: inability to cooperate with inhalation therapy rapidly decompensating patient failure to respond to inhaled beta-agonists
15
Status Asthmaticus Anticholinergics agonist Sympathetic Vagolytics Parasympatheti c X Airway
16
Status Asthmaticus Inhaled Ipratropium + Albuterol 120 children - severe acute asthma: FEV 1 < 50% Albuterol (0.15 mg/kg) x 3 within 60 minutes PLUS Randomized: control saline ipratropium 250 mcq x 1 ipratropium 250 mcg x 3 -Schuh, J Peds, 1995
17
Status Asthmaticus Effect of Inhaled Ipratropium * * * * * * * * p <.05 -Schuh, J Peds, 1995
18
Ipratropium: Effect with FEV 1 < 30% -Schuh, J Peds, 1995 * p <.05 * * * * * * *
19
Status Asthmaticus IV or oral Corticosteroids Mechanism of Effect: interferes with leukotriene, prostaglandins synthesis prevent cell migration up-regulate airway receptors
20
Status Asthmaticus IV or oral Corticosteroids Proven effective in 3 level I trials, meta- analysis Decreased hospital admission if given within 30 minutes Equally effective oral or IV IV dose effect in 1-6 hours by reversing 2 receptor down-regulation
21
Status Asthmaticus IV or oral Corticosteroids Recommended dose Prednisone or methylprednisolone suggested initial dose 2 mg/kg 1 mg/kg IV q 6 hours (max 60 mg) x 48 hours, then 1mg/kg q 12 hours for 3-5 days -NHLBI Expert Panel
22
Status Asthmaticus Inhaled Corticosteroids SI asthma has several characteristic features severe asthma with persistent respiratory symptoms frequent nighttime symptoms chronic airflow obstruction (FEV 1 <70% of predicted) tend to have required systemic GC therapy at a younger age require higher daily maintenance doses of oral GCs are often African American.
23
Status Asthmaticus Inhaled Corticosteroids Acute Asthma ICS have been considered ineffective in treatment of acute exacerbations Nevertheless, many studies published in the last 15 years have showed therapeutic early effects (after minutes of its administration) suggesting a different mechanism of action of topical character
24
Status Asthmaticus Inhaled Corticosteroids Acute Asthma These rapid effects are initiated by specific interactions with membrane-bound or cytoplasmic CS receptors, or nonspecific interactions with the cell membrane asthmatic patients present a significant increase in airway mucosal blood flow
25
Status Asthmaticus Inhaled Corticosteroids Acute Asthma ICS would decrease blood flow by modulating sympathetic control of vascular tone This nongenomic action might reduce the airway obstruction, improving clinical and spirometric parameters Furthermore, the decrease of airway blood flow is likely to enhance the action of inhaled bronchodilators by diminishing their clearance from the airway
26
Status Asthmaticus Long term inhaled corticosteroid Most studies done on moderate to severe persistent asthma (beneficial) Data on mild or moderate and intermittent not well studied Studies by O‘Byrne et al and Lange et al reinforce current practice of preventing asthma events with the regular use of ICS in patients who have symptoms on most days
27
Status Asthmaticus IV Theophylline Phosphodiesterase inhibitor Randomized trials (x2) - no benefit over standard 2 agonists and/or corticosteroids Uncertain benefit in episodes unresponsive to all other therapy
28
Status Asthmaticus IV Theophylline 21 hospitalized children Standard nebulized albuterol, steroids Randomized: IV Aminophylline load/infusion OR Saline placebo -Carter, J Peds, 1993
29
Status Asthmaticus IV Theophylline No difference in hospital days No difference in hospital days Confirmed by another study Confirmed by another study - Carter, J Peds, 1993
30
IV Theophylline in Severe Pediatric Asthma -Carter, J Peds, 1993
31
“Methylxanthines are NOT generally recommended.” -Expert Panel, NAEPP
32
Status Asthmaticus Ketamine Dissociative anesthetic Direct bronchodilator Potentiates catecholamines Bronchorrhea Other side effects: tachycardia BP
33
Status Asthmaticus Ketamine Adult studies Case reports: benefit in avoiding intubation Randomized trials: no added benefit required lower dose due to dysphoria Children might respond better, less dysphoria
34
Status Asthmaticus Ketamine in Pediatrics 8 case reports: 12 patients - not controlled 8 months - 14 years Positive affect in all 9/12 intubated Bolus/Infusion 0.2 - 2.5 mg/kg/hr
35
Status Asthmaticus Ketamine in Pediatrics One small pediatric study in non- intubated patients 10 patients ketamine bolus plus 1 hr infusion in addition to standard therapy Improved CAS improved indicators of distress
36
Status Asthmaticus Magnesium Sulfate Bronchodilator: inhibits cellular Ca ++ uptake/release stabilizes most cell membranes Clinical effect: 10/13 studies showed improved PEFR in adults, children 2 adult studies no outcome benefit
37
Status Asthmaticus Magnesium Sulfate 31 children (6-18 yrs) in ER Asthma exacerbation: PEFR < 60% after albuterol Randomized: MgSO 4 25 mg/kg OR Saline -Ciarallo, J Peds, 1996
38
Status Asthmaticus Magnesium Sulfate -Ciarallo, J Peds, 1996 * * * * * * p <.05
39
Status Asthmaticus Magnesium Sulfate -Ciarallo, J Peds, 1996 * * * * * * p <.05
40
Status Asthmaticus Magnesium Sulfate Results: ER discharge home: 27% vs 0% control (p =.03) No difference in hospital stay No significant side effects -Ciarallo, J Peds, 1996
41
Status Asthmaticus Leukotriene Antagonist Mostly used as controller med Some newer small studies to suggest possible benefit in acute setting Rapid improvement in FEv1 with single IV monoleukast dose (Thorax 2000; 55:260-5) 160 mg Po Zafirlukast improved ER outcomes ( Ann Emerg Med 2000; 35:S10
42
Status Asthmaticus Helium - Oxygen (HELIOX) Blend of 80:20 helium:oxygen Biologically inert Insoluable in human tissue No deleterious effects Low density gas Air: 1.29 g/l O 2 : 1.43 g/l Helium: 0.17 g/l
43
Status Asthmaticus Helium - Oxygen (HELIOX) Major effects to reduce resistance: Reduces turbulence Used in upper airway obstruction Improved pulsus paradoxus, PEFR in adult asthmatics
44
Status Asthmaticus Helium - Oxygen (HELIOX) Most recent case reports and clinical studies have found mixed results in the role of heliox for use in asthma
45
Status Asthmaticus Helium - Oxygen (HELIOX) Kudukis et al showed that heliox therapy resulted in a significant decrease in pulsus paradoxus, a decrease in a modified dyspnea index, and an increase in peak flow Manthous et al reported similar findings in dyspnea index and pulsus paradoxus accompanied by an increase in peak expiratory flow. Rivera et al the heliox group had a lower admission rate compared with the placebo group (60% vs 81%). Other studies have shown a decrease in carbon dioxide, reversal of acidosis, and an increase in peak expiratory flow rate
46
Status Asthmaticus Helium - Oxygen (HELIOX) Carter et al found that short-term inhalation of heliox offered no benefit in hospitalized children with severe asthma. Henderson et al found that 3 treatments of albuterol nebulized in heliox over 45 minutes offered no additional benefit in the ED management of mild to moderate asthma exacerbations Rose et al found that heliox-driven continuous albuterol in the ED management no difference in peak expiratory flow rate, respiratory rate, or oxygen saturation
47
Status Asthmaticus Inhaled Anesthetics Halothane, enflurane, isoflurane Mechanisms: 2 agonist effect vagolytic direct airway relaxation No randomized (level I) trials
48
Status Asthmaticus Inhaled Anesthetics 8 pediatric case reports: effect in 7/8 isoflurane 5/8 Duration 1-34 hrs; Time interval for changes: 1-2 hrs Complications: hypotension, pneumothorax
49
Response to Inhaled Anesthetics pCO 2 PIP
50
Status Asthmaticus “ Mechanical” Support BiPAP Intubation/Mechanical Ventilation Extracorporeal Life Support
51
Status Asthmaticus Non invasive Ventilation Positive-pressure by nasal mask (BiPAP) Potential benefits: airway stenting improve V/Q match CPAP improved hypoxemia in 8 asthmatic children
52
Status Asthmaticus Non invasive Ventilation 26 children (+ 7.2 years) in PICU 19/26 managed without intubation: RR, HR, SaO 2 7/26 intubated 11/26 BiPAP held Efficacy remains uncertain -Teague, Lang, et al, ATS, 1998
53
Status Asthmaticus Non invasive Ventilation Beers et al immediate improvement in subjects' clinical status upon initiation of BiPAP, with 77% showing a decrease in respiratory rate, averaging 23.6% (range, 4%-50%), and 88% showing an improved oxygen saturation, averaging 6.6 percentage points (1-28 percentage points). There were no adverse events due to the use of BiPAP.
54
Status Asthmaticus Nitric Oxide Smith et al showed that F E NO measurements provide a useful guide about whether benefits will be obtained from a trial of ICS treatment. the response to inhaled fluticasone for 4 weeks was significantly greater than placebo and occurred predominantly in the ⅓ of subjects whose F E NO was greater than 47 ppb In the absence of high F E NO levels, a response to steroid was much less likely
55
Status Asthmaticus Nitric Oxide Exhaled nitric oxide (F E NO) surrogate marker for eosinophilic airway inflammation. F E NO may be used to guide steroid requirements High F E NO levels may be used to predict likely benefits with inhaled corticosteroid (ICS) repeated F E NO measurements improve the cost- effectiveness of ICS therapy when used to guide dose requirements
56
Status Asthmaticus Intubation Usually last resort Potential M&M Mortality rate in adults 0 - 40% in children 0 - 5% 24-33% of PICU admissions required mechanical ventilation (very high?)
57
Status Asthmaticus Intubation Wear Depends ! Intubation by MD with experience Have volume ready: hypotension due to ed intrathoracic pressure
58
Status Asthmaticus Intubation Best done semi-electively earlier rather than later Drugs of choice: Atropine Ketamine/Midazolam Succinylcholine
59
Status Asthmaticus Mechanical Ventilation GOALS: Rest inspiratory muscles Protect airway Provide adequate gas exchange NOT normal exchange Avoid barotrauma, catastrophe
60
Status Asthmaticus Mechanical Ventilation Indications Coma Respiratory or cardiac arrest Cyanosis and hypoxemia on O 2 PaCO 2 greater than 50 and rising > 5mmHg/hr Deteriorating mental status Minimal chest movement/air exchange Pneumothorax Absolute: Relative:
61
Status Asthmaticus Mechanical Ventilation Key approach: permissive hypercapnia (“controlled hypoventilation”) tolerate pCO 2 to keep pH > 7.20 - 7.25 prolonged expiratory time rate, inspiratory time tidal volume PEEP: auto-PEEP
62
Status Asthmaticus Extracorporeal Membrane Oxygenation Venovenous bypass for life support in asthma unresponsive to all other therapy Membrane lung extremely efficient at CO 2 clearance, low-flow Allows for bronchoscopy
63
Status Asthmaticus Extracorporeal Membrane Oxygenation 60 pediatric patients pCO 2 at cannulation: 37-284 mmHg Maximal therapy 83% survival 7 here who all survived without sequelae
64
Therapies NOT Recommended Antibiotics Empiric, aggressive hydration Chest PT Mucolytics Sedation??
65
Evidence-Based Guidelines: Report Card A: GOOD evidence to recommend for USE of treatment B: FAIR evidence to recommend for USE C: POOR evidence to support recommendation, but USE recommended on other grounds D : FAIR evidence to recommend EXCLUSION F : GOOD evidence to recommend EXCLUSION -CMAJ, 1993
66
Report Card: Status Asthmaticus Therapy Oxygen C Agonists InhaledA+ InhaledA+ IVB IVB Ipratropium A Corticosteroids A Methylxanthines D
67
Report Card: Status Asthmaticus Therapy Magnesium B+ KetamineC HELIOX B- Inhaled Anesthesia C+ BiPAPC+
68
Questions??
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.